What if the difference between a seamless tech transfer and a costly setback isn't your process, but how you orchestrate the people and details behind the scenes?

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann shares hard-earned lessons on the complexities of tech transfer and scale-up in the biotech industry.

Key Topics Discussed

• Tech transfer success depends heavily on understanding human dynamics, not just technical factors.
• Stakeholder resistance often stems from hidden pressures, making empathy and perspective crucial.
• Effective stakeholder management requires early mapping, tailored communication, and trust-building.
• Systematic troubleshooting, including environmental factors, is key to resolving unexpected process differences.
• Scale-up success relies on controlling variables like mixing, kLa, and equipment differences through structured checks.
• The build vs. outsource decision must balance long-term strategy, expertise, and resource efficiency.
• A structured 12-week preparation protocol reduces risk through phased planning, mitigation, and execution readiness.
• Strong leadership involves delegation and focusing on high-impact work to avoid burnout and improve outcomes.

Episode Highlights

• How mapping and managing stakeholders can resolve hidden issues and accelerate projects [01:55]
• Case studies highlighting the importance of environmental factors — like light exposure — in process performance and troubleshooting [05:50]
• A mass transfer checklist for bioprocess scale-up, with specific focus on equipment-related parameters [07:09]
• The build vs. outsource dilemma: how to choose what to keep in-house and what to partner out, depending on company strategy and project phase [08:05]
• A 12-week tech transfer preparation protocol, covering foundations, risk mitigation, and execution readiness [10:16]
• Lessons on leadership, prioritization, and effective delegation to avoid personal and organizational bottlenecks [13:28]

Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC

Implementation Playbook

In Part 1, you learned the six-pillar framework. Now I'm giving you the implementation playbook—starting with the human element that most people completely miss.

Pillar 4 in Action: Stakeholder Management

Story time. I was leading a tech transfer to a new manufacturing site. Everything was progressing—slowly, but progressing. Except for one guy in QC. Every interaction was difficult. Analysis requests were unpredictable. My team was stressed. His team seemed stressed. Walls were going up.

I was convinced he was the problem. Resistant to change. Maybe territorial about his lab.

Then I did something I should've done weeks earlier. I walked into his lab. No agenda. Just a conversation.

Turns out? He wasn't resistant. He was drowning. His lab was understaffed. His backlog was crushing. And every time we showed up with an "urgent" sample request, it threw his entire week into chaos.

He craved predictability. I was creating chaos.

Once I understood that, everything changed. We built a sampling calendar to give him a longer term view.

The transformation was immediate. Not because the science changed. Because I finally understood what he needed.

Here's the lesson: Understanding stakeholder needs is as critical as understanding the process.

Now, your stakeholder protocol.

1️⃣ First, map early. Identify every stakeholder: QC, QA, manufacturing ops, process development, regulatory, even facilities and IT if your process has special requirements.

2️⃣ Second, understand motivations. What does each stakeholder need? What are their fears? The QC manager might fear analytical backlogs. The QA manager might fear audit findings. The manufacturing supervisor might fear unproven procedures. Write it down.

3️⃣ Third, communication plan. Match frequency and method to stakeholder type. Some people want weekly written updates. Some want face-to-face check-ins every two weeks. Some just want to know you'll call them if there's a problem.

4️⃣ Fourth, use the Power-Interest Grid. Focus your energy on high-power, high-interest stakeholders. They're the ones who can kill your project or accelerate it.

5️⃣ Fifth, build trust face-to-face whenever possible. Especially for the resisters. Email doesn't build trust. Video calls are better than nothing. But nothing beats sitting in someone's space and listening.

Pillar 1 in Action: Scale-Up Physics

Another story. We transferred a process to a new site. Identical equipment specs. Identical SOPs. We'd even sent people for hands-on training.

First batch at the new site? Completely different performance. Lower viability. Lower titer. Different impurity profile.

We spent months troubleshooting. Tested everything. Media? Same lot numbers. Seed train? Same frozen vials. Bioreactor control? Same setpoints. Environmental monitoring? All in spec.

Finally, after exhausting every rational explanation, someone noticed the obvious. Different light exposure.

We ran a controlled study. Light exposure was affecting the culture. Not enough to trigger an out-of-spec environmental reading. Enough to change cell behavior.

The lesson? List ALL differences upfront—and even then, expect surprises. Environmental factors matter. Light. Temperature fluctuations in the room. Vibration from nearby equipment. Document everything, even the "obvious" stuff.

Now, your mass transfer checklist.

Calculate scale-down ratios for key parameters. Mixing time increases with scale—you need to plan for that. Power per volume is typically kept constant. kLa—oxygen transfer—plan for a decrease. Impeller tip speed is a major consideration for shear-sensitive products.

Run scale-down models at the receiving site before you commit to full scale. This isn't optional. You need to prove the physics work in their equipment with their utilities.

And document everything. Not just the process parameters. The room temperature range. The water quality specs. The equipment maintenance history. The things that live in people's heads and never make it into batch records.

Pillar 6 in Action: Build vs. Outsource

Decision framework time.

When to build internal? Platform technology you'll use repeatedly. If you're a monoclonal antibody company planning five programs over three years, in-house manufacturing starts making sense. Core competitive advantage in manufacturing—if your IP is in the process, not just the molecule, you might need to keep it in-house. Commercial volumes that justify capital investment. Or absolute control requirements over IP and process knowledge.

When to outsource? Novel modality with uncertain commercial potential. Need speed to clinic—CDMOs have infrastructure ready today. Limited capital for facility investment. Or strategic redundancy—testing multiple CDMOs so you're not dependent on a single partner.

Matthias Müllner gave us the insight: External CMC expertise bridges gaps early—build internal capability gradually. You don't need to decide everything day one. Start with outsourced. Learn what you actually need. Then selectively insource the pieces that create competitive advantage.

Your 12-Week Tech Transfer Preparation Protocol

📅 Weeks 1 through 4: Foundation.

Define your Quality Target Product Profile and Critical Quality Attributes with the receiving site. Not at them. With them. Map the stakeholder landscape using the protocol we just covered. Create a detailed tech transfer plan document—this becomes your contract with yourself. And identify which parameters are scale-dependent versus scale-independent.

📅 Weeks 5 through 8: Risk Mitigation.

Conduct a gap assessment. Equipment, methods, training needs. Qualify raw materials at the receiving site—source, vendor approval, comparability. You cannot assume your supplier has the same qualification status at their site. Run scale-down models at the receiving site. Develop a comprehensive sampling plan with statistical power. Train receiving site personnel—and I don't mean train them on SOPs. Train them on the why. Why does this step matter? What happens if it goes wrong? What are the early warning signs?

And here's the critical one: Document tribal knowledge. Capture the undocumented tricks. The environmental nuances. The operator expertise that lives only in people's heads. The way your senior operator knows the culture is stressed before the dissolved oxygen trace shows it. Write that down.

📅 Weeks 9 through 12: Execution Preparation.

Co-author batch records with the receiving site. Not you write, they review. Co-author.

Establish communication protocols—who calls whom when something goes sideways? Define success criteria and go/no-go decision points. Plan for contingencies—if the scale-down model fails, what's plan B?

Go/no-go decision points. You don't proceed to full scale unless:

• Scale-down model achieves comparable results.
• All CQAs have validated analytical methods at the receiving site.
• Key personnel are trained and can demonstrate understanding.
• Raw materials are qualified and available.

If any critical gap remains, you stop. You do not proceed to full scale hoping it'll work out. Hope is not a strategy.

The Delegation Lesson

Early in my career, I thought I needed to control everything. Write all the protocols. Review all the data. Draft all the reports.

Result? I became the bottleneck. Burned out. And paradoxically, progress slowed.

The turning point came when I got an assistant for admin and protocol and report writing. Suddenly, I had time for the things only I could do. Strategic decisions. Stakeholder relationships. Critical technical judgment calls.

The insight that changed everything: As a leader, focus on the 20% that only you can do. I further honed this as an entrepreneur. You have limited hours and limited attention span. If you spend them on the 80% that someone else could do, you're stealing from the 20% that creates actual value.

Your action item this week: Identify your 80% activities. Then plan to delegate them within 90 days. Not someday. Within 90 days.

Conclusion

You're staring at a tech transfer timeline. Leadership wants aggressive dates. The CDMO is confident but vague. And you're carrying the weight of knowing that if this slips, the entire program slips.

That pressure? It's real. The complexity? Also real.

But here's what's also real. Tech transfer isn't magic. It's not an art. It's building on six essential pillars with discipline and foresight.

You've got the framework now. Technical process understanding—know what's scale-dependent. Analytical comparability—design it upfront. Quality by Design—define your CQAs before the crisis. Stakeholder management—understand what people need. Partner selection—choose the CDMO that challenges you. Strategic build versus buy—focus on competitive advantage.

You've got the 12-week protocol. Foundation, risk mitigation, execution preparation.

And you've got the mindset shift. Master the human element. Understand the physics. Plan systematically. Delegate the 80% that doesn't require your unique expertise.

Your "piece of cake" tech transfer? It can actually be cake. Not because tech transfer got easier. Because you got better at orchestrating complexity.

The timeline's not going to get less aggressive. The stakeholders aren't going to get less demanding. But you now have a system that works regardless.

Go make it happen.

If you liked today’s conversation about scale-up and tech transfer, please tell us by leaving a review. Your review helps scientists like you discover these resources.

For additional bioprocessing tips, visit us at www.smartbiotechscientist.com. Stay tuned for more inspiring biotech insights in the next episode. Until then, let’s continue to smarten up biotech.

Disclaimer: This transcript was generated with the assistance of artificial intelligence. While efforts have been made to ensure accuracy, it may contain errors, omissions, or misinterpretations. The text has been lightly edited and optimized for readability and flow. Please do not rely on it as a verbatim record.

Next Step

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Further Listening

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger

Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra

Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

He is also a biotech technology innovation coach, technology transfer leader, and host of the Smart Biotech Scientist podcast—the go-to podcast for biotech scientists who want to master biopharma CMC development and biomanufacturing.  

Hear It From The Horse’s Mouth

Want to listen to the full interview? Go to Smart Biotech Scientist Podcast. 

Want to hear more? Do visit the podcast page and check out other episodes. 
Do you wish to simplify your biologics drug development project? Contact Us